Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: Differing response in relation to presynaptic dopaminergic dysfunction

Synapse

Volumn 27, Issue 4, 1997, Pages 336-346

  Ruottinen, Hanna M ^a   Rinne, Juha O ^a   Oikonen, Vesa J ^b   Bergman, Jörgen R ^c   Haaparanta, Merja T ^c   Solin, Olof H ^c   Ruotsalainen, Ulla H ^b   Rinne, Urpo K ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c TURKU PET CENTRE   (Finland)

Author keywords

Catechol O methyltransferase; Entacapone; Fluorodopa; Monoamine oxidase B; Parkinson's disease; Selegiline

Indexed keywords

6 FLUORODOPA F 18; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE; AMINE OXIDASE (FLAVIN CONTAINING); ANTIPARKINSON AGENT; DIAGNOSTIC AGENT; DOPA; DOPAMINE; DRUG DERIVATIVE; ENZYME INHIBITOR; FLUORINE; FLUORODOPA F 18; MONOAMINE OXIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ENZYME INHIBITION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; CASE CONTROL STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RADIOASSAY; SYNAPTOSOME;

ADULT; AGED; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE; ENZYME INHIBITORS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PRESYNAPTIC TERMINALS; RADIOLIGAND ASSAY; SELEGILINE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030609109     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199712)27:4<336::AID-SYN7>3.0.CO;2-D     Document Type: Article

References (41)

1. Aquilonius, S.-M., and Eckernäs, S.-Å. (1980) A Colour Atlas of the Human Brain. Esselte studium, Stockholm, Sweden.
2. Bergman, J., Källman, K.-M., Solin, O., DeJesus, O.T., Oakes, T.R., and Nickles, R.J. (1993) A new method for the production of electrophilic F-18 starting from aqueous [F-18] fiuoride. J. Nucl. Med. Abstr., 34:69P.
3. 18F]-fluoride. J. Label. Compounds Radiopharm. Abstr., 35:476-477.
4. Birkmayer, W. (1978) Long term treatment with L-deprenyl. J. Neural. Transm., 43:239-244.
5. 18F]FDOPA) in humans. J. Cereb. Blood Flow Metab., 13:668-675.
6. 18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. J. Neurochem., 63:1675-1682.
7. Fahn, S., Elton, R.L., and members of the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Recent Developments in Parkinson's Disease, Vol. 2. S. Fahn, C.D. Marsden, M. Goldstein, and D.B. Calne, eds. Macmillan Healthcare Information, Florham Park, NJ, pp. 153-163.
8. Floud, A., and Fahn, S. (1981) L-dopa (L-3,4-dihydroxyphenylalanine) uptake by human red blood cells. Biochim. Biophys. Acta, 645:165-169.
9. 18F]fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine. Proc. Natl. Acad. Sci. U. S. A., 75:464-467.
10. Gjedde, A. (1982) Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: A re-examination. Brain Res. Rev., 4:237-274.
11. Gjedde, A., Reith, J., Dyve, S., Léger, G., Guttman, M., Diksic, M., Evans, A., and Kuwabara, H. (1991) Dopa decarboxylase activity of the living human brain. Proc. Natl. Acad. Sci. U. S. A., 88:2721-2725.
12. 18F]fluoro-L-dopa in rhesus monkey. Nucl. Med, Biol., 22:921-927.
13. Guttman, M., Léger, G., Cedarbaum, J.M., Reches, A., Woodward, W., Evans, A., Diksic, M., and Gjedde, A. (1992) 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann. Neurol., 31:638-643.
14. Guttman, M., Léger, G., Reches, A., Evans, A., Kuwabara, H., Cedarbaum, J.M., and Gjedde, A. (1993) Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov. Disord., 8:298-304.
15. Heinonen, E.H., Rinne, U.K., and Tuominen, J. (1989) Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. Acta Neurol. Scand., 126:113-118.
16. Hoehn, M.M., and Yahr, M.D. (1967) Parkinsonism: Onset, progression, and mortality. Neurology, 17:427-442.
17. Holden, J.E., Pate, B.D., Snow, B.J., Chan, G.L.-Y., Chutskoff, T.L., Endres, C.E., Ruth, T.J., and Calne, D.B. (1992) Effects of simultaneous inhibition of MAO-B and COMT on striatal L-6-fluorodopa kinetics in non-human primates. In: Medical Application of Cyclotrons VI. L.-M. Voipio-Pulkki and U. Wegelius, eds. Gillot Oy, Turku, Finland, pp. A89-A90.
18. 18F]fluoro-L-DOPA metabolism in living human brain: A comparison of six analytical methods. J. Cereb. Blood Flow Metab., 13:57-69.
19. Ishikawa, T., Dhawan, V., Chaly, T., Robeson, W., Belakhlef, A., Mandel, F., Dahl, R., Margouleff, C., and Eidelberg, D. (1996) Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: Effect of the plasma 3-O-methyldopa fraction on data analysis. J. Cereb. Blood Flow Metab., 16:854-863.
20. Kaakkola, S., Gordin, A., and Männistö, P.T. (1994) General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen. Pharmac. Rev., 25:813-824.
21. R) facilitates the activity of the nigrostriatal dopaminergic neuron. J. Neural. Transm. Suppl., 25:45-66.
22. Kuruma, I., Bartholini, G., Tissot, R., and Pletscher, A. (1971) The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin. Pharmacol. Ther., 12:678-682.
23. 18F]fluoro-dopamine is enhanced in patients with Parkinson's disease. J. Nucl. Med., 34:31P.
24. 18F]fluoro-DOPA and positron emission tomography: Error analysis and application to normal subjects. J. Cereb. Blood Flow Metab., 13:43-56.
25. Kuwabara, H., Cumming, P., Yasuhara, Y., Léger, G.C., Guttman, M., Diksic, M., Evans, A.C., and Gjedde, A. (1995) Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. J. Nucl. Med., 36:1226-1231.
26. 18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology, 42:199-203.
27. Li, X.-M., Juorio, A.V., Paterson, I.A., Zhu, M.-Y., and Boulton, A.A. (1992) Specific irreversible monoamine oxidase B inhibitors stimulate gene expression of aromatic L-amino acid decarboxylase in PC12 cells. J. Neurochem., 59:2324-2327.
28. Lyytinen, J., Kaakkola, S., Teräväinen, H., Ahtila, S., Naukkarinen, T., and Gordin, A. (1994) Comparison between selegiline and placebo in combination with L-dopa and entacapone in Parkinson's disease (PD). Mov. Disord. Abstr., 9:82.
29. 18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Brain Res., 626:1-13.
30. 18F]fluoro-L-dopa. Appl. Radiat. Isot., 43:989-996.
31. Paterson, I.A., Davis, B.A., Durden, D.A., Juorio, A.V., Yu, P.H., Ivy, G., Milgram, W., Mendonca, A., Wu, P., and Boulton, A.A. (1995) Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain. Neurochem. Res., 20: 1503-1510.
32. Patlak, C.S., and Blasberg, R.G. (1985) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab., 5:584-590.
33. Patlak, C.S., Blasberg, R.G., and Fenstermacher, J.D. (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab., 3:1-7.
34. Riederer, P., and Youdim, M.B.H. (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J. Neurochemistry, 46:1359-1365.
35. 18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect., 10:91-106.
36. 18F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease. Neurology, 44:1292-1297.
37. Snow, B.J., Vingerhoets, F.J.G., Holden, J.E., Sossi, V., Chan, G.L.Y., Buckley, K.R., Morrison, K.S., Ruth, T., Jorga, K., Pedder, S., and Dingemanse, J. (1996) The effect of tolcapone on central and peripheral COMT activity in normal humans and Parkinson's disease: A PET study. Mov. Disord. Abst., 11:195.
38. Tekes, K., Tóthfalusi, L., Gaál, J., and Magyar, K. (1988) Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol. J. Pharmacol. Pharm., 40:653-658.
39. Vrana, S.L., Azzaro, A.J., and Vrana, K.E. (1992) Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway. Mol. Pharmacol., 41:839-844.
40. Wade, L.A., and Katzman, R. (1975) 3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci., 17:131-136.
41. Zsilla, G., Földi, P., Held, G., Székely, A.M., and Knoll, J. (1986) The effect of repeated doses of(-)deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol. J. Pharmacol. Pharm., 38:57-67.